Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ado-Over: FDA Uses Prefix To Get Ahead Of Pull-Down Menu Problem

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

The use of computer drop-down menus organized by generic name was identified as a source of medication errors in the clinical program, mixing up Kadcyla with unconjugated trastuzumab. The solution of adding a three-letter prefix to Kadcyla’s nonproprietary name also seems to be the fix for biosimilars.

You may also be interested in...



Review Of Reviews: Drug Review Profiles 2013

Pharmaceutical Approvals Monthly’s Drug Review Profile stories from 2013.

Review Of Reviews: Drug Review Profiles 2013

Pharmaceutical Approvals Monthly’s Drug Review Profile stories from 2013.

Teva’s G-CSF Product Clears FDA, Leaving Appeal Of Biosimilar Pathway Uncertain

Teva is the first company to get FDA approval of a version of Amgen’s Neupogen; one biosimilar expert questions why Teva did not switch its BLA to a biosimilar application when that pathway became available.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

GB150348

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel